NASDAQ:INZY Inozyme Pharma (INZY) Stock Price, News & Analysis $0.87 -0.04 (-4.40%) Closing price 04:00 PM EasternExtended Trading$0.92 +0.05 (+5.75%) As of 04:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Inozyme Pharma Stock (NASDAQ:INZY) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Inozyme Pharma alerts:Sign Up Key Stats Today's Range$0.86▼$0.9350-Day Range$0.91▼$1.5252-Week Range$0.86▼$7.80Volume454,171 shsAverage Volume494,834 shsMarket Capitalization$55.89 millionP/E RatioN/ADividend YieldN/APrice Target$14.56Consensus RatingBuy Company OverviewInozyme Pharma, Inc., a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, as well as patients with end-stage kidney disease receiving hemodialysis. It has a license agreement with Yale University for specified therapeutic and prophylactic products. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.Read More… Remove Ads Inozyme Pharma Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks73rd Percentile Overall ScoreINZY MarketRank™: Inozyme Pharma scored higher than 73% of companies evaluated by MarketBeat, and ranked 249th out of 930 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.5 / 5Analyst RatingBuy Consensus RatingInozyme Pharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 9 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageInozyme Pharma has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Inozyme Pharma's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Inozyme Pharma are expected to decrease in the coming year, from ($1.59) to ($1.64) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Inozyme Pharma is -0.56, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Inozyme Pharma is -0.56, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioInozyme Pharma has a P/B Ratio of 0.38. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Inozyme Pharma's valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted9.16% of the float of Inozyme Pharma has been sold short.Short Interest Ratio / Days to CoverInozyme Pharma has a short interest ratio ("days to cover") of 5.8.Change versus previous monthShort interest in Inozyme Pharma has recently decreased by 9.11%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldInozyme Pharma does not currently pay a dividend.Dividend GrowthInozyme Pharma does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted9.16% of the float of Inozyme Pharma has been sold short.Short Interest Ratio / Days to CoverInozyme Pharma has a short interest ratio ("days to cover") of 5.8.Change versus previous monthShort interest in Inozyme Pharma has recently decreased by 9.11%, indicating that investor sentiment is improving significantly. News and Social Media2.8 / 5News Sentiment1.08 News SentimentInozyme Pharma has a news sentiment score of 1.08. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.78 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Inozyme Pharma this week, compared to 2 articles on an average week.Search Interest10 people have searched for INZY on MarketBeat in the last 30 days. This is an increase of 233% compared to the previous 30 days.MarketBeat FollowsOnly 7 people have added Inozyme Pharma to their MarketBeat watchlist in the last 30 days. This is a decrease of -13% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Inozyme Pharma insiders have not sold or bought any company stock.Percentage Held by Insiders11.19% of the stock of Inozyme Pharma is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions88.30% of the stock of Inozyme Pharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Inozyme Pharma's insider trading history. Receive INZY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Inozyme Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address INZY Stock News HeadlinesInozyme Pharma to Participate in the 24th Annual Needham Virtual Healthcare ConferenceMarch 31 at 8:30 AM | globenewswire.comInozyme Pharma (INZY) Gets a Buy from Bank of America SecuritiesMarch 17, 2025 | markets.businessinsider.comA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same indicator that helped me call the bear market of 2018... the bull market in 2020... the bear market in 2022... the roaring bull markets in 2023 and 2024... and more. I'm convinced it has helped me identify the next big crash too. We are at an important juncture in the markets. Knowing what to do in the months to come is critical.April 1, 2025 | Chaikin Analytics (Ad)Inozyme price target lowered to $12 from $24 at Raymond JamesMarch 12, 2025 | markets.businessinsider.comInozyme Pharma Focuses on ENPP1 Deficiency ProgramMarch 11, 2025 | tipranks.comAnalysts Offer Insights on Healthcare Companies: Inozyme Pharma (INZY) and Urogen Pharma (URGN)March 10, 2025 | markets.businessinsider.comInozyme reports prioritization of ENPP1 Deficiency program, workforce reductionMarch 10, 2025 | markets.businessinsider.comInozyme reports FY24 EPS ($1.62), consensus ($1.51)March 10, 2025 | markets.businessinsider.comSee More Headlines INZY Stock Analysis - Frequently Asked Questions How have INZY shares performed this year? Inozyme Pharma's stock was trading at $2.77 at the start of the year. Since then, INZY stock has decreased by 68.6% and is now trading at $0.87. View the best growth stocks for 2025 here. How were Inozyme Pharma's earnings last quarter? Inozyme Pharma, Inc. (NASDAQ:INZY) issued its quarterly earnings results on Tuesday, November, 5th. The company reported ($0.39) EPS for the quarter, beating the consensus estimate of ($0.44) by $0.05. When did Inozyme Pharma IPO? Inozyme Pharma (INZY) raised $75 million in an initial public offering on Friday, July 24th 2020. The company issued 5,000,000 shares at $14.00-$16.00 per share. BofA Securities, Cowen and Piper Sandler served as the underwriters for the IPO and Wedbush PacGrow was co-manager. How do I buy shares of Inozyme Pharma? Shares of INZY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Inozyme Pharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that Inozyme Pharma investors own include Salesforce (CRM), Home Depot (HD), Chevron (CVX), Coca-Cola (KO), Meta Platforms (META), QUALCOMM (QCOM) and AbbVie (ABBV). Company Calendar Last Earnings11/05/2024Today4/01/2025Next Earnings (Estimated)5/06/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:INZY CIK1693011 Webwww.inozyme.com Phone857-330-4340FaxN/AEmployees50Year FoundedN/APrice Target and Rating Average Stock Price Target$14.56 High Stock Price Target$23.00 Low Stock Price Target$7.00 Potential Upside/Downside+1,584.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage9 Analysts Profitability EPS (Most Recent Fiscal Year)($1.63) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-71,170,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-88.42% Return on Assets-57.02% Debt Debt-to-Equity Ratio0.51 Current Ratio7.68 Quick Ratio7.68 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.27 per share Price / Book0.38Miscellaneous Outstanding Shares64,240,000Free Float57,052,000Market Cap$55.50 million OptionableOptionable Beta1.32 7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report This page (NASDAQ:INZY) was last updated on 4/1/2025 by MarketBeat.com Staff From Our PartnersTrump’s Secret WeaponHave you looked at the stock market recently? Millions of investors are scrambling trying to figure out what's...American Alternative | SponsoredA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredTrump Allies Confirm Exec Order 14024 Triggers Dollar CollapseExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsMusk confirmed that SpaceX's Starship will carry Optimus to Mars in 2026 as part of an autonomous mission to h...InvestorPlace | SponsoredRetirement Nightmare? It’s Already Happening.The market is on edge. Every day, another company slashes its dividend, leaving investors scrambling. Intel...Investors Alley | SponsoredNew “Trump” currency proposed in DCA former U.S. Presidential Advisor has come forward with a stern warning to investors: “Get out of tech, no...Paradigm Press | SponsoredIs Fort Knox Hiding Less Gold Than We Think? Find Out What That Means for YouWith gold prices recently soaring to record highs over $3,000 an ounce, and central banks rushing to accumulat...The Oxford Club | SponsoredHuge Elon-backed AI rollout begins – buy these nine stocksIf you suspect Elon Musk has an ulterior motive for coming to Washington, D.C.... You're 100% correct. ...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Inozyme Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Inozyme Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.